AbbVie’s Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer DrugsOn Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57.Net revenues reached $14.46 billion, up 4.3%, beating...
